Insulinoma other imaging findings

Jump to navigation Jump to search

Insulinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Insulinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Insulinoma other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Insulinoma other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Insulinoma other imaging findings

CDC on Insulinoma other imaging findings

Insulinoma other imaging findings in the news

Blogs on Insulinoma other imaging findings

Directions to Hospitals Treating Insulinoma

Risk calculators and risk factors for Insulinoma other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]

Overview

The other imaging studies include positron emission tomography (PET) and somatostatin receptor Scintigraphy (SRS) which are nuclear studies used for detecting somatostatin receptor especially subtype 2 using radioisotopes of Gallium. The increased uptake of radioligands is suggestive of insulinoma. The metastasis also shows the increased uptake. The sensitivity of PET is increased by doing a CT scan coupled with PET scan. The sensitivity of SRS is 50 to 60% as insulinomas have less somatostatin subtype 2 receptor which is detected by the test.

Other Imaging Findings

Positron emission tomography|Positron Emission Tomography

Insulinoma-PET Scan.;Case courtesy of Radswiki, Radiopaedia.org, rID: 11670

Somatostatin receptor scintigraphy

Insulinoma-Octreoscan;Case courtesy of Radswiki, Radiopaedia.org, rID: 11670

Findings on an SRS suggestive of insulinoma include:

References

  1. Sadowski SM, Neychev V, Cottle-Delisle C, Merkel R, Yang LA, Quezado MM, Chang R, Kebebew E (2014). "Detection of insulinoma using (68)Gallium-DOTATATE PET/CT: a case report". Gland Surg. 3 (4): E1–5. doi:10.3978/j.issn.2227-684X.2014.10.02. PMC 4244512. PMID 25493261.
  2. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ (2007). "68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT". J. Nucl. Med. 48 (4): 508–18. PMID 17401086.
  3. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wängler B, Uebleis C, Schmidt GP, Göke B, Bartenstein P, Hacker M (2012). "The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors". J. Nucl. Med. 53 (11): 1686–92. doi:10.2967/jnumed.111.101675. PMID 22984220.
  4. Zimmer T, Stölzel U, Bäder M, Koppenhagen K, Hamm B, Buhr H; et al. (1996). "Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas". Gut. 39 (4): 562–8. PMC 1383270. PMID 8944566.
  5. Proye C, Malvaux P, Pattou F, Filoche B, Godchaux JM, Maunoury V; et al. (1998). "Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy". Surgery. 124 (6): 1134–43, discussion 1143-4. PMID 9854595.
  6. McAuley, G.; Delaney, H.; Colville, J.; Lyburn, I.; Worsley, D.; Govender, P.; Torreggiani, W.C. (2005). "Multimodality preoperative imaging of pancreatic insulinomas". Clinical Radiology. 60 (10): 1039–1050. doi:10.1016/j.crad.2005.06.005. ISSN 0009-9260.
  7. Behr T, Becker W, Koch W, Grebmeier J, Wolf F (1994). "[Somatostatin receptor scintigraphy in neuroendocrine tumors exemplified by a patient with hepatic metastases of gastrinoma]". Z Gastroenterol. 32 (2): 100–4. PMID 7513113.
  8. Jensen RT, Gibril F, Termanini B (1997). "Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization". Yale J Biol Med. 70 (5–6): 481–500. PMC 2589266. PMID 9825476.

Template:WH Template:WS ​​